Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | BioInformant Reports | Opportunities in Human Embryonic Stem Cells

Opportunities in Human Embryonic Stem Cells

Overview: Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reach 4-5 days post fertilization. hESCs are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body.

hESCs were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research.

Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. Of particular interest to the medical community is the potential for use of hESCs to heal tissues with naturally limited capacity for renewal, such as the human heart, liver and brain.

This market report recognizes that a wide range of products and services are needed to support this active and well-funded research community. Thus, this report provides:

* Discussion of key advances in hESC research

* A breakdown of hESC research applications, including shared priorities and priorities by segment

* hESC patent analysis

* Historical and future growth projections for the hESC market

* Competitive analysis of providers of hESC research tools

* Overview of specialty pharma companies developing hESC therapies

* Overview of toxicology testing legislation impacting use of hESC in toxicology applications

* A breakdown of hESC research product categories

* Suggestions for novel NSC research products, including cells, kits, assays, media and reagents

* Guidance for companies that wish to offer hESCs products

* And more…

December 2008 Format: PDF
Table of Contents
Price: $3,495.00 / €2,338.16

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions